Replimune Group(REPL)

产业链观察06-06 19:27

#药闻简讯# 2024年6月6日，临床阶段的生物技术公司$Replimune Group(REPL)$ 今天宣布了RP1联合纳武利尤单抗治疗抗PD1失败黑色素瘤的IGNYTE临床试验初步分析的顶线结果。独立中心评价的结果显示，接受RP1联合纳武利尤单抗治疗的患者中有三分之一对治疗有反应，这比ASCO 2024上公布的研究者评估数据...查看全文

年度财报

Replimune Group(REPL)05-16 20:25

$Replimune Group(REPL)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001737953-24-000008  Act: 34  Size: 10 MB 网页链接查看全文

当期报告

Replimune Group(REPL)05-16 20:15

$Replimune Group(REPL)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001104659-24-062296  Act: 34  Size: 287 KB 网页链接查看全文

当期报告

Replimune Group(REPL)06-13 20:45

$Replimune Group(REPL)$ 8-K Current report, items 1.01, 3.02, 7.01, and 9.01 Accession Number: 0001104659-24-071078  Act: 34  Size: 743 KB 网页链接查看全文

证券出售报告

Replimune Group(REPL)06-08 04:55

$Replimune Group(REPL)$ 144 Report of proposed sale of securities Accession Number: 0001968582-24-000475  Act: 33  Size: 4 KB 网页链接查看全文

其他

Replimune Group(REPL)07-20 04:25

$Replimune Group(REPL)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001104659-24-081170  Act: 34  Size: 1 MB 网页链接查看全文

持股变动声明

Replimune Group(REPL)05-21 08:15

$Replimune Group(REPL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-063563  Size: 5 KB 网页链接查看全文

其他

Replimune Group(REPL)05-16 20:15

$Replimune Group(REPL)$ POSASR Post-effective Amendment to an automatic shelf registration statement Accession Number: 0001104659-24-062298  Act: 33  Size: 762 KB 网页链接查看全文

员工持股计划

Replimune Group(REPL)05-16 21:15

$Replimune Group(REPL)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001104659-24-062326  Act: 33  Size: 126 KB 网页链接查看全文

持股变动声明

Replimune Group(REPL)05-21 08:15

$Replimune Group(REPL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-063562  Size: 5 KB 网页链接查看全文

雪楼2020-11-20 18:11

$Replimune Group(REPL)$ 融留病毒第一查看全文

Grando2020-01-15 22:49

$Replimune Group(REPL)$ 关注的人太少了，溶瘤病毒配合PD-1很牛逼的呀。都临床二期效果真不错，而且都是大适应症啊，空间很大查看全文

李斯特Lis2018-08-08 21:48

$Replimune Group, Inc.(REPL)$ 每半小时成交一笔。查看全文

跟上K叔2018-07-23 13:34

$Replimune Group, Inc.(REPL)$ 免疫肿瘤查看全文

生效批准

$Replimune Group(REPL)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-24-002213  Act: 33  Size: 1 KB 网页链接

股东委托书协议

$Replimune Group(REPL)$ DEF 14A Other definitive proxy statements Accession Number: 0001104659-24-081167  Act: 34  Size: 1 MB 网页链接

其他

$Replimune Group(REPL)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001104659-24-081170  Act: 34  Size: 1 MB 网页链接

其他

$Replimune Group(REPL)$ ARS Annual Report to Security Holders Accession Number: 0001104659-24-081174  Act: 34  Size: 9 MB 网页链接

超过5%股东持股披露「修订」

$Replimune Group(REPL)$ SC 13G/A [Amend] Statement of Beneficial Ownership by Certain Investors Accession Number: 0000093751-24-000657  Act: 34  Size: 8 KB 网页链接

当期报告

$Replimune Group(REPL)$ 8-K Current report, items 1.01, 3.02, 7.01, and 9.01 Accession Number: 0001104659-24-071078  Act: 34  Size: 743 KB 网页链接

持股变动声明

$Replimune Group(REPL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-070108  Size: 5 KB 网页链接

证券出售报告

$Replimune Group(REPL)$ 144 Report of proposed sale of securities Accession Number: 0001968582-24-000475  Act: 33  Size: 4 KB 网页链接

当期报告

$Replimune Group(REPL)$ 8-K Current report, items 7.01, 8.01, and 9.01 Accession Number: 0001104659-24-068948  Act: 34  Size: 6 MB 网页链接

当期报告

$Replimune Group(REPL)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001104659-24-067556  Act: 34  Size: 226 KB 网页链接